Bayer drug gets orphan label

Share this article:
Bayer drug gets orphan label
Bayer drug gets orphan label

Bayer HealthCare landed an orphan-drug designation for its experimental inhaled ciprofloxacin dry powder, designed to treat patients with non-cystic fibrosis bronchiectasis.

The condition, which occurs in patients who do not have cystic fibrosis, refers to bronchial tube scarring and inflammation, which make it difficult to clear mucous. The British Lung Foundation estimates that around 25% of cases have no known cause, but some cases are associated with scarring caused by whooping cough or pneumonia and reduced immunity after an infection, among other causes.

Symptoms include recurring infections and a persistent cough.

Bayer's proposed treatment is for intermittent use.

Recently approved orphan drugs include the likes of Eli Lilly's oncology treatment Cyramza.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...